Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Frontiers in Oncology, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen +13 more
doaj +2 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]
Journal of Ovarian Research, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj +2 more sources
Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]
PLoS ONE, 2013 Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Sabine B Weitensteiner +8 more
doaj +12 more sources
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma [PDF]
IJU Case Reports, 2020 Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto +8 more
doaj +2 more sources
Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen +4 more
doaj +2 more sources
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Abdelhakim Salem +5 more
doaj +2 more sources
Acta Pharmaceutica Sinica B, 2020 Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment.
Zongru Jiang +14 more
doaj +3 more sources
An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis
Scientific Reports, 2023 Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar +5 more
doaj +1 more source
Journal of Dental Sciences, 2021 Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear.
Shin-ichi Yamada +8 more
doaj +1 more source